216 related articles for article (PubMed ID: 12592331)
1. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
Yetgin S; Tuncer MA; Cetin M; Gümrük F; Yenicesu I; Tunç B; Oner AF; Toksoy H; Koç A; Aslan D; Ozyürek E; Olcay L; Atahan L; Tunçbilek E; Gürgey A
Leukemia; 2003 Feb; 17(2):328-33. PubMed ID: 12592331
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization.
Yetgin S; Gürgey A; Tuncer AM; Cetin M; Ozbek N; Sayli T; Güler E; Kara A; Olcay L; Duru F; Gümrük F; Atahan L; Tunçbilek E
Leuk Res; 1998 Jun; 22(6):485-93. PubMed ID: 9678714
[TBL] [Abstract][Full Text] [Related]
3. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments.
Alikasifoglu A; Yetgin S; Cetin M; Tuncer M; Gumruk F; Gurgey A; Yordam N
Am J Hematol; 2005 Oct; 80(2):113-8. PubMed ID: 16184587
[TBL] [Abstract][Full Text] [Related]
5. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
6. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
[TBL] [Abstract][Full Text] [Related]
7. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
8. Myeloprotective effect of short-course high-dose methylprednisolone treatment before consolidation therapy in children with acute myeloblastic leukemia.
Elmas SA; Cetin M; Tuncer M; Hiçsönmez G
Am J Hematol; 2005 Sep; 80(1):1-5. PubMed ID: 16138333
[TBL] [Abstract][Full Text] [Related]
9. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Yetgin S; Cetin M
Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
[TBL] [Abstract][Full Text] [Related]
10. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
11. The effect of high-dose methylprednisolone combined chemotherapy on CD34-positive cells in acute lymphoblastic leukemia.
Tuncer AM; Hiçsönmez G; Gümrük F; Albayrak D; Duru F; Güzel E; Sayli T
Hematol Pathol; 1994; 8(4):169-75. PubMed ID: 7532164
[TBL] [Abstract][Full Text] [Related]
12. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999.
Tsuchida M; Ohara A; Manabe A; Kumagai M; Shimada H; Kikuchi A; Mori T; Saito M; Akiyama M; Fukushima T; Koike K; Shiobara M; Ogawa C; Kanazawa T; Noguchi Y; Oota S; Okimoto Y; Yabe H; Kajiwara M; Tomizawa D; Ko K; Sugita K; Kaneko T; Maeda M; Inukai T; Goto H; Takahashi H; Isoyama K; Hayashi Y; Hosoya R; Hanada R;
Leukemia; 2010 Feb; 24(2):383-96. PubMed ID: 20033052
[TBL] [Abstract][Full Text] [Related]
16. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T
Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
[TBL] [Abstract][Full Text] [Related]
17. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
18. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
19. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
